Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Molecular Biotechnology|October 26, 2012
With or without sugar? (A)glycosylation of therapeutic antibodiesDmitrij Hristodorov, Rainer Fischer, Lars LindenImmunology and Cell Biology|January 9, 2016
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophagesDmitrij Hristodorov, Radoslav Mladenov, Rainer Fischer, et al.Toxins|October 30, 2012
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseasesDmitrij Hristodorov, Radoslav Mladenov, Michael Huhn, et al.Mabs|December 18, 2014
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapyDmitrij Hristodorov, Radoslav Mladenov, Hannes Brehm, et al.Molecular Biotechnology|March 20, 2012
Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodiesDmitrij Hristodorov, Rainer Fischer, Hannah Joerissen, et al.Progress in Retinal and Eye Research|January 13, 2024
Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investmentDmitrij Hristodorov, Tim Lohoff, Nanna Luneborg, et al.British Journal of Haematology|October 30, 2013
Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivoDmitrij Hristodorov, Johannes Nordlohne, Radoslav Mladenov, et al.Biomedicines|June 28, 2017
Human MAP Tau Based Targeted Cytolytic Fusion ProteinsOlusiji A Akinrinmade, Sandra Jordaan, Dmitrij Hristodorov, et al.Mabs|July 29, 2015
Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsiesDmitrij Hristodorov, Radoslav Mladenov, Verena von Felbert, et al.Cancer Letters|April 19, 2015
Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion proteinHannes Brehm, Dmitrij Hristodorov, Alessa Pardo, et al.Pageof 2